Biocon's Biosimilar Blues
The Morning Brief
00:00
Biocon Biologics - Is There a Higher Leverage?
Sreas tambe, deputy c of biocon biologics, had to say on the possible reasons why the disconnect happened. He said it's always possible that it requires a higher leverage than we're used to. And in this case, i now we've got to deal where we've actually risk balanced it with a a consideration of three billion dollars being broken up into two components - part cash and part equity.
Play episode from 11:59
Transcript
